PFE Stock Recent News

The final trades of the day with CNBC's Mike Santoli and the “Fast Money” traders.

Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings results and cost-cutting efforts.

Pfizer Inc. (NYSE:PFE ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de Germay - Executive VP & Chief International Commercial Officer Andrew Simon Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development David M. Denton - CFO & Executive VP Francesca M.

Shares of the large pharmaceutical company Pfizer (PFE 5.18%) closed up over 5% today after a strong earnings report that included raising its full-year profit outlook for 2025.

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth in Primary Care, Specialty Care, and Oncology, but looming patent expiries and regulatory risks persist. Management's financial discipline is improving, with cost savings, debt management, and a focus on extracting value from recent M&A deals.

Evan David Seigerman, BMO Capital Markets managing director & healthcare head, joins CNBC's 'Squawk on the Street' to discuss outlooks on Pfizer.

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.

The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.